MediciNova's two core compounds, MN-221 and MN-166, are both involved in ongoing Phase II/IIb clinical trials. We are currently interested in strategic partnership discussions to support further development of both programs and would consider both partnership and investment opportunities. Although our non-core compounds do not have clinical trials ongoing at this time, we are pursuing partnership opportunities to continue their development.
If you would like to discuss any of our compounds as potential licensing, acquisition or investment opportunities, please contact our Business Development department:
Director, Business Development
4275 Executive Square, Suite 650
La Jolla, CA 92037